drugset / Trial / NCT00270400

A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure

NCT00270400

Phase 3 Completed 255 enrolled Scios, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effects on heart rate and ventricular arrhythmias (irregular heart beats) of two doses of Natrecor® (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) versus dobutamine, during the first 24 hours of treatment of decompensated congestive heart failure (CHF).

Timeline

Start
1998-08
Primary completion
Completion
1999-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.015 ug/kg Intravenous
Subject Nesiritide Protein / enzyme biologic 0.03 ug/kg Intravenous